Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
3.12 x 5 3.19 x 2
Pre-market by (Cboe BZX)
3.18 -0.13 (-3.93%) 03/20/25 [NASDAQ]
3.12 x 5 3.19 x 2
Pre-market 3.14 -0.04 (-1.26%) 07:00 ET
Quote Overview for Thu, Mar 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.06
Day High
3.33
Open 3.28
Previous Close 3.31 3.31
Volume 1,646,400 1,646,400
Avg Vol 2,359,725 2,359,725
Stochastic %K 54.90% 54.90%
Weighted Alpha -38.38 -38.38
5-Day Change +0.41 (+14.80%) +0.41 (+14.80%)
52-Week Range 2.75 - 9.97 2.75 - 9.97
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 400,232
  • Shares Outstanding, K 125,859
  • Annual Sales, $ 0 K
  • Annual Income, $ -110,780 K
  • EBIT $ -112 M
  • EBITDA $ -104 M
  • 60-Month Beta 1.36
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 156.96% ( +59.55%)
  • Historical Volatility 81.04%
  • IV Percentile 79%
  • IV Rank 41.74%
  • IV High 273.17% on 12/09/24
  • IV Low 73.71% on 02/20/25
  • Put/Call Vol Ratio 0.21
  • Today's Volume 1,151
  • Volume Avg (30-Day) 3,365
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 89,359
  • Open Int (30-Day) 70,057

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.23
  • Number of Estimates 3
  • High Estimate -0.22
  • Low Estimate -0.25
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +4.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.75 +15.64%
on 03/13/25
Period Open: 3.75
3.94 -19.29%
on 02/27/25
-0.57 (-15.20%)
since 02/20/25
3-Month
2.75 +15.64%
on 03/13/25
Period Open: 4.64
5.66 -43.82%
on 12/27/24
-1.46 (-31.47%)
since 12/20/24
52-Week
2.75 +15.64%
on 03/13/25
Period Open: 3.51
9.97 -68.10%
on 05/31/24
-0.33 (-9.40%)
since 03/20/24

Most Recent Stories

More News
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvessâ„¢ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

HUMA : 3.18 (-3.93%)
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvessâ„¢ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

HUMA : 3.18 (-3.93%)
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

HUMA : 3.18 (-3.93%)
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvessâ„¢ and Other Bioengineered Tissues

HUMA : 3.18 (-3.93%)
Humacyte Announces Commercial Launch of Symvessâ„¢ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

HUMA : 3.18 (-3.93%)
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVPâ„¢) Development Using iPSCs

HUMA : 3.18 (-3.93%)
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEVâ„¢ for Coronary Artery Bypass Grafting

HUMA : 3.18 (-3.93%)
Humacyte Provides Update on Commercial Launch and Pricing of Symvessâ„¢ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

HUMA : 3.18 (-3.93%)
Humacyte Stock Hits Over 1-Month Highs On FDA Nod For Bioengineered Tissue In Treating Vascular Trauma, Retail Interest Soars

Real-world evidence from its humanitarian use in Ukraine to treat wartime injuries further bolstered the company’s biologics license application.

HUMA : 3.18 (-3.93%)
Humacyte, Inc. Announces FDA Approval for SYMVESS as First-in-Class Bioengineered Vascular Conduit for Arterial Injury Repair

Humacyte's SYMVESS receives FDA approval as a bioengineered vascular conduit with promising clinical outcomes for arterial injury repair.Quiver AI SummaryHumacyte, Inc. has announced that the FDA has granted...

HUMA : 3.18 (-3.93%)

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 3.60
2nd Resistance Point 3.46
1st Resistance Point 3.32
Last Price 3.18
1st Support Level 3.05
2nd Support Level 2.91
3rd Support Level 2.77

See More

52-Week High 9.97
Fibonacci 61.8% 7.21
Fibonacci 50% 6.36
Fibonacci 38.2% 5.51
Last Price 3.18
52-Week Low 2.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals